The effect of Cisplatin on Complete blood count among chemotherapy Sudanese patients at Taiba Cancers Center in Khartoum state 2021

Background: Cisplatin is one of therapy used as anticancer activity in a variety of tumors. Among many chemotherapy drugs that are widely used for cancer, Cisplatin is one of the most compelling ones. Material and methods: This study was Analytical cross sectional study conducted at Taiba Cancer Center, Khartoum, Sudan, during the period July 2021 to November 2021 and aimed to estimate the complete blood count among chemotherapy Sudanese patients treated with Cisplatin. 50 cancer patients treated with cisplatin as chemotherapy selected as a case group and 50 apparently health donor were selected as control group. Three ml of the venous blood was collected in EDTA container. Six sample collected from each patient before each dose of cisplatin. Complete blood count was done by using Sysmex Automated Hematology Analyzer KX 21N.Result: When compared the base line of case value of RBCs, Hb, WBCs, neutrophils, and platelets with control there were insignificant differences (P. value ≥ 0.05). But when compared RBCs, Hb, WBCs, neutrophils, and platelets between the case (baseline) and the cases in cycle 1, 2,3,4 and 5 there was significant decreased among progression of doses (P. value ≤ 0.05). There was insignificant correlation in the duration of the cancer and WBCs, neutrophil count, HGB and platelets count (P. value ≥ 0.05), significant correlation with RBCs in baseline and cycle 2 (P. value < 0.05). When correlate the anatomical location of cancer with WBCs, neutrophil count there was insignificant correlation, and significant correlation with RBC and HGB in cycle 5 and platelets count cycle 2 and cycle 3 Conclusion: The study observed that Cisplatin with combination of drug can effect on the hematological parameters also the chemotherapy was induced anemia, neutropenia and thrombocytopenia.